Remove axys
article thumbnail

3rd TIGIT Axis Therapies Summit

pharmaphorum

The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor, blood cancer and non-oncology setting. View the full agenda here.

article thumbnail

Study Highlights PBMs’ Role in Drug Prices

Pharmaceutical Commerce

An analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistencies on the prices of both generics and branded products.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

First CAR T-cell therapy recommended on NHS

European Pharmaceutical Review

Yescarta ® ▼(axicabtagene ciloleucel; axi-cel) is now the first chimeric antigen receptor (CAR) T-cell therapy and first personalised immunotherapy to be recommended for routine use on the NHS in England. Since then, over 500 patients in England have received axi-cel.

article thumbnail

SAEM Clinical Images Series: Unusual Scalp Lesions

ALiEM - Pharm Pearls

cm in the long axis diameter.” In short axis, there is an echogenic lesion with surrounding fluid (halo sign) suggesting a foreign body that also exhibits posterior acoustic shadowing. Symptoms did not improve despite completion of treatment. Laboratory Data Non-contributory Case Question: What are the ultrasound findings?

article thumbnail

Research Shows Supporting Gut-Lung Axis Can Prevent Lung Disease

Pharmacy Times

People have been taking probiotics to support digestive health for centuries, but researchers in the pulmonary field have turned their attention toward how microbiome science can be used to support the lungs.

52
article thumbnail

USFDA accepts NextPoint Therapeutics’s IND for NPX887

Pharmaceutical Business Review

NextPoint Therapeutics chief medical officer Leena Gandhi said: “NPX887 represents our second clinical program targeting the HHLA2 checkpoint axis. NextPoint’s approach is to advance therapeutics targeting this axis from different angles to prevent tumours from cloaking themselves from the immune system.

article thumbnail

Potential best-in-class antibody shows “remarkable efficacy” in atopic dermatitis

European Pharmaceutical Review

Dr Yufang Lu added that “given the important role of the OX40-OX40L axis in the pathogenesis of a spectrum of immunological and inflammatory diseases, IMG-007 could be suitable for a number of indications”. Final findings from the Phase IIa atopic dermatitis trial are expected in Q3 2024.

120
120